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RESULTS

OBJECTIVE
• To evaluate the appropriateness of inpatient rifaximin use and healthcare resource
utilization best-practices within a community health-system.

BACKGROUND
• Rifaximin is a non-systemic, gastrointestinal site-specific antibiotic, with a wide spectrum
of antibacterial activity against aerobic and anaerobic gram-positive and gram-negative
organisms. It acts by inhibiting bacterial ribonucleic acid (RNA) synthesis.1
• Rifaximin is FDA approved for three indications: treatment of traveler’s diarrhea (TD)
caused by noninvasive strains of Escherichia coli, the reduction in risk of hepatic
encephalopathy (HE) recurrence, and treatment of irritable bowel syndrome with
diarrhea (IBS-D).2
• Off-label uses, supported by literature, include the treatment of HE episodes,
Clostridioides difficile infections (CDI), and small intestinal bacterial overgrowth
(SIBO).3,4,5
• As evidence-based indications for rifaximin have expanded since it first reached the
market in 2010, so has its utilization within the organization.
• The goal of this study is to ensure the clinically appropriate and cost-effective use of
rifaximin, while maintaining optimal therapeutic outcomes.

Table 2. Baseline Characteristics
Characteristic
Age (mean age in years ± SD)
Male (n, %)
Listed Indication (n, %)
• HE Treatment
• HE Prevention
• SIBO
• IBS-D
• TD
• CDI
Rifaximin Use Prior to Admission (n, %)
Lactulose Use Prior to Admission (n, %)
Figure 1. Appropriateness of
Rifaximin Orders

RESULTS
n = 300
56.7 ± 12.4
163 (54.3%)
149 (49.7%)
139 (46.3%)
6 (2.0%)
4 (1.3%)
1 (0.3%)
1 (0.3%)
162 (54.0%)
173 (57.7%)

Figure 2. Number of Tablets Administered & Associated
Costs Based on Average Wholesale Price

METHODS
• A retrospective chart review was conducted on inpatients for whom rifaximin was
ordered between August 1, 2018 – July 31, 2019.
• Within this timeframe, rifaximin was ordered 487 times. Of these, 300 random orders
were assessed and included in this study.
• Endpoints:
o Primary – appropriate use of rifaximin, including indication, dose, and frequency
o Secondary – cost, indications, and reasons associated with appropriate vs
inappropriate use, and new starts versus continuations of home rifaximin
• Appropriate use was defined by evidence available for each indication, including FDAapproved indications or as recommended by current guidelines, or after failure of or
contraindication to use of alternatives as noted in Table 1.1-8
Table 1. Criteria for Appropriate Inpatient Rifaximin Use
Indication
Criteria
HE Prevention
• Continuation of home rifaximin as an add-on to
lactulose, and > 1 HE episode is charted; or
• Intolerance or contraindication to lactulose, and > 1
HE episode is charted
HE Treatment Lactulose, rifaximin, or both prior to admission:
• As an add-on to lactulose
Neither lactulose or rifaximin prior to admission:
• Add-on to lactulose, after 24h of lactulose
monotherapy, or
• Intolerance or contraindication to lactulose
TD
• Treatment failure, allergies, or contraindications to
first-line therapies (azithromycin, fluoroquinolones)
IBS-D
• Use alternative (which may include home supplied
rifaximin)
CDI
• Second or subsequent recurrence (or history
unknown); and
• Previously tried: pulsed-tapered vancomycin, or
fidoxamicin, or nitazoxanide, or fecal transplant
SIBO
• Treatment failure to > 1 prior gastrointestinal-targeted
antibiotic regimen

Figure 3. Appropriateness of Rifaximin Orders Based on Indication
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550 mg BID

400 mg TID
or
550 mg BID

200 mg TID
--400 mg TID

550 mg TID

Figure 6. Appropriateness of New Starts of Rifaximin vs Continuations of Home Rifaximin

DISCUSSION & CONCLUSIONS
• Of the 300 rifaximin orders placed within the study timeframe, 47% were considered
inappropriate, indicating an opportunity for improvement regarding the practice of
evidence-based, clinically appropriate, cost-effective inpatient rifaximin use.
o Almost all orders for non-HE conditions, and nearly half of HE indications, were
considered inappropriate.
o The majority of inappropriate usage was seen in patients who were not on
rifaximin prior to admission. However, a quarter of home rifaximin continuations
were also inappropriate.
• Challenges involving appropriate inpatient use likely lie in its strict criteria for initiation,
such as an adequate trial of first-line therapies, and the reliance on a robust
documentation of a patient’s past-medical history.
• Future directions should involve leveraging the electronic medical record to improve
ordering and follow-up for patients receiving rifaximin, such as prompting the provider
for documentation of prior agent use or contraindication at the time of ordering.
• Pharmacists can play a key role in establishing the judicious use of inpatient rifaximin
through the assessment of dosages and frequencies based on a stated indication, if
available, and assessing appropriate trial of first-line therapies.
o Currently, this health system has a clinical monitoring alert for pharmacists to
assess all patients receiving rifaximin. Next steps will include evaluating alert
saliency for inappropriate orders placed in this timeframe, and using this
information to tailor strategies for increasing clinically appropriate use.
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